Company news

Annexon, Inc. news in 2026

Annexon, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

October 28, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2026

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

September 24, 2026

Annexon to Participate in Upcoming September Investor Conferences

September 2, 2026

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

August 12, 2026

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

August 12, 2026

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

August 10, 2026

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

August 6, 2026

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

July 30, 2026

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

July 14, 2026

Annexon to Participate in Upcoming June Investor Conferences

May 27, 2026

Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4)

May 19, 2026

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 7, 2026

Annexon to Present at the Bank of America Securities Health Care Conference 2026

May 6, 2026

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

March 29, 2026

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

February 17, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

January 12, 2026

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

January 8, 2026

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Calls in 2026

Decks in 2026